Conway Kevin John

Conway Kevin John, Chief Financial Officer of GBIO, has engaged in a pattern of transactions primarily involving the disposition of shares in the company, as reflected in SEC Form 4 filings. Over 26 reported trades, Conway has recorded no purchases, with all activity consisting of sales totaling $877.59. The transactions, largely coded as "F" (payment of exercise price or tax liability) or "M" (open market), show a recurring pattern of stock disposals tied to equity compensation events. Notably, on February 2, 2026, Conway sold shares worth $406.08—the largest single transaction—followed by smaller dispositions on January 15, 2026 ($95.88), October 15, 2025 ($120.78), July 15, 2025 ($73.70), and January 15, 2025 ($181.15). The filings also include a cluster of transactions on February 9, 2026, coded as "D" (disposition to the issuer) and "U" (disposition under Rule 16b-6(e)), though these carried no reported dollar value. The absence of any buy transactions suggests Conway has not increased his position in GBIO during the observed period. The sales appear systematic, likely tied to vesting schedules or tax obligations rather than discretionary market trades. While the dollar amounts are relatively modest, the consistency of dispositions over multiple quarters indicates an ongoing reduction in holdings. No recent transactions suggest a shift in this trend.